Neurometabolic Profile of Individuals With Primary Mitochondrial Disease
Children's Hospital of Philadelphia · NCT06890520
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 8–75 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 30
- US sites recruiting
- 1
- Study start
- February 25, 2025
- Record last updated
- February 5, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Primary Mitochondrial Disease (PMD) is a genetic neurometabolic disorder, leading to central nervous system degeneration and increased risk of early mortality. There is a strong link between the pathophysiology of mitochondrial disease and biomarkers related to the biochemistry of redox imbalance, involving the levels of glutathione. Investigators will use Magnetic Resonance Imaging and Spectroscopy to non-invasively measure glutathione and other chemicals in the brain to identify redox imbalance in patients with PMD.
Conditions: Primary Mitochondrial Disease
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Must be between 8 and 75 years, inclusive
- Genetically confirmed primary mitochondrial disease
- Receiving standard-of-care treatment including mitochondrial supplements that may include N-acetylcysteine (NAC), a precursor of glutathione
Inclusion Criteria for Healthy Controls
- Must be between 8 and 75 years, inclusive
Exclusion Criteria
- MRI contraindications
- In the investigator's opinion, inability to fully comply with research procedures
- Active self-reported alcohol and/or substance abuse, including tobacco-use
- A pacemaker; any metal-based medical or non-medical devices/implants; any non-removable metal-based object (e.g., body piercings, jewelry, etc.) that cannot be cleared through radiologic evaluation
- Any history of intraocular injury or fragment in or around the orbit that cannot be cleared through radiologic evaluation
- Any history of bullet, shrapnel, or stabbing wounds that cannot be cleared through radiologic evaluation
- Past or current employment involving (or exposure to) a metal grinder (e.g., at a construction worksite)
- At the discretion of the principal investigator (PI), any medical condition that will interfere with or prevent the safe completion of the study
- Any female participant with childbearing potential who is knowingly pregnant or suspects that she is pregnant will be removed from the study. (Although there are no known risks of MRI on pregnant females or fetuses, there is a possibility of yet undiscovered pregnancy-related risks. Since there is no direct benefit from participating in this protocol for pregnant females, they will be excluded to ensure their long-term safety and that of their unborn fetus.)
- To note, for this protocol, participants are instructed to lie still in the MRI scanner; there is no contrast or sedation. Participants who do not possess the cognitive and / or physical abilities to perform these procedures will not be included.
Recruiting US locations
The Children's Hospital of Philadelphia
Philadelphia, PA 19104
Site contact: Zarazuela Zolkipli-Cunningham · 267-426-4961 · mmfpclinicalresearch@chop.edu
Study contacts (from the official record)
- Zarazuela Zolkipli-Cunningham · (267) 426-4961 · mmfpclinicalresearch@chop.edu
Similar studies in Pennsylvania
All healthy volunteers studies in Pennsylvania →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC
Melissa Pugliano-Mauro
- Location
- Pittsburgh, PA
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1/Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
- Location
- Philadelphia, PA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Philadelphia, PA + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
Novo Nordisk A/S
- Location
- Hershey, PA + 4 other US sites
- Eligibility basics
- Ages 18–64 · Men only